SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CELC

Celcuity Inc. (NASDAQ:CELC)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$53.35-$2.96 (-5.26%)
 
Market cap
$2.61B
Insider Score
Health Score
Analyst consensus
Listed since
Sep 19, 2017
Market Cap$2.61B-47.3%
Revenue (ttm)$0
Net Income-$256.01M-57.3%
EPS-$4.70-28.1%
Shares Out48.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume636,527
Open$55.02
Previous Close$56.31
Day's Range$53.22 - $57.00
52-Week Range$53.20 - $151.02
Beta0.16
AnalystsBuy
Price Target$160.67(+201.16%)
Earnings DateMar 24, 2027

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Address
2800 Campus Drive, Minneapolis, MN, 55441, US
Market Cap
2.61 billion
Employees
155
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$322.86M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $158.70 (+197.5%)

4 firms rating CELC in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From CELC’s reported statements · Q3 2026 (trailing 12 months) · 3 of 5 pillars

Next catalysts

1 Day
-5.26%
5 Days
-17.73%
1 Month
-18.64%
6 Months
-61.40%
1 Year
-47.26%

$CELC stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of CELC by members of U.S. Congress

Tom MalinowskiHouseSale$1.00K – $15.00KMay 26, 2021
Tom MalinowskiHousePurchase$1.00K – $15.00KJun 18, 2020

Recently reported changes in CELC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CELC's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CELC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CELC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CELC from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CELC

VTIVanguard Morningstar Total Stock Market ETF$76.52M
XBIState Street SPDR S&P Biotech ETF$69.09M
IWMiShares Russell 2000 ETF$56.60M
VXFVanguard Extended Market ETF$32.34M
IWOiShares Russell 2000 Growth ETF$20.47M
VTWOVanguard Russell 2000 ETF$15.64M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CELC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: FDA acceptance of supplemental application for breast cancer indication represents concrete regulatory progress with meaningful clinical potential.

Recent Insider Activity

Buys
0
Sells
11
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CANCTema Oncology ETF1.38%
SGRWHarbor Active Small Cap Growth ETF (SGRW)0.94%
XBIState Street SPDR S&P Biotech ETF0.78%
BBCVirtus Biotech Clinical Trials ETF0.54%
TDNAT. Rowe Price Biotech ETF0.49%
HELXFranklin Genomic Advancements ETF0.33%
ACSGAmerican Century Small Cap Growth Insights ETF0.32%
VTWGVanguard Russell 2000 Growth ETF0.20%
SSMGVirtus Silvant Small/Mid Growth ETF0.17%
IWOiShares Russell 2000 Growth ETF0.16%
PWSPacer WealthShield ETF0.15%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.15%

Weight is the stock’s share of each fund’s holdings.